Michel Zeitouni1, Anna Giczewska1, Renato D Lopes1, Daniel M Wojdyla1, Christina Christersson2, Agneta Siegbahn3, Raffaele De Caterina4, Philippe Gabriel Steg5, Christopher B Granger1, Lars Wallentin6, John H Alexander7. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 2. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden. 3. Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center (UCR), Uppsala, Sweden. 4. Division of Cardiovascular Medicine, Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy. 5. Cardiology Department, AP-HP, Hôpital Bichat, FACT, Université de Paris and INSERM, Paris, France. 6. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center (UCR), Uppsala, Sweden. 7. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. Electronic address: john.h.alexander@duke.edu.
Abstract
BACKGROUND: In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and ≥2 dose-adjustment criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dl [133 μmol/l]) were randomized to receive apixaban 2.5 mg twice daily or warfarin. OBJECTIVES: The purpose of this study was to describe the effects of apixaban dose adjustment on clinical and pharmacological outcomes. METHODS:Patients receiving the correct dose of study drug were included (n = 18,073). The effect of apixaban 2.5 mg twice daily versus warfarin on population pharmacokinetics, D-dimer, prothrombin fragment 1 + 2 (PF1+2), and clinical outcomes was compared with the standard dose (5 mg twice daily). RESULTS: Patients receiving apixaban 2.5 mg twice daily exhibited lower apixaban exposure (median area under the concentration time curve at a steady state 2,720 ng/ml vs. 3,599 ng/ml; p < 0.0001) than those receiving the standard dose. In patients with ≥2 dose-adjustment criteria, reductions in D-dimers (p interaction = 0.20) and PF1+2 (p interaction = 0.55) were consistent with those observed in the standard-dose population. Patients with ≥2 dose-adjustment criteria (n = 751) were at higher risk for stroke/systemic embolism, major bleeding, and all-cause death than the standard-dose population (0 or 1 dose-adjustment criterion, n = 17,322). The effect of apixaban 2.5 mg twice daily versus warfarin in the ≥2 dose-adjustment criteria population was consistent with the standard dose in the reductions in stroke or systemic embolism (p interaction = 0.26), major bleeding (p interaction = 0.25), and death (p interaction = 0.72). CONCLUSIONS:Apixaban drug concentrations were lower in patients receiving 2.5 mg twice daily compared with 5 mg twice daily. However, the effects of apixaban dose adjustment to 2.5 mg versus warfarin were consistent for coagulation biomarkers and clinical outcomes, providing reassuring data on efficacy and safety. (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation [ARISTOTLE]; NCT00412984).
RCT Entities:
BACKGROUND: In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and ≥2 dose-adjustment criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dl [133 μmol/l]) were randomized to receive apixaban 2.5 mg twice daily or warfarin. OBJECTIVES: The purpose of this study was to describe the effects of apixaban dose adjustment on clinical and pharmacological outcomes. METHODS:Patients receiving the correct dose of study drug were included (n = 18,073). The effect of apixaban 2.5 mg twice daily versus warfarin on population pharmacokinetics, D-dimer, prothrombin fragment 1 + 2 (PF1+2), and clinical outcomes was compared with the standard dose (5 mg twice daily). RESULTS:Patients receiving apixaban 2.5 mg twice daily exhibited lower apixaban exposure (median area under the concentration time curve at a steady state 2,720 ng/ml vs. 3,599 ng/ml; p < 0.0001) than those receiving the standard dose. In patients with ≥2 dose-adjustment criteria, reductions in D-dimers (p interaction = 0.20) and PF1+2 (p interaction = 0.55) were consistent with those observed in the standard-dose population. Patients with ≥2 dose-adjustment criteria (n = 751) were at higher risk for stroke/systemic embolism, major bleeding, and all-cause death than the standard-dose population (0 or 1 dose-adjustment criterion, n = 17,322). The effect of apixaban 2.5 mg twice daily versus warfarin in the ≥2 dose-adjustment criteria population was consistent with the standard dose in the reductions in stroke or systemic embolism (p interaction = 0.26), major bleeding (p interaction = 0.25), and death (p interaction = 0.72). CONCLUSIONS:Apixaban drug concentrations were lower in patients receiving 2.5 mg twice daily compared with 5 mg twice daily. However, the effects of apixaban dose adjustment to 2.5 mg versus warfarin were consistent for coagulation biomarkers and clinical outcomes, providing reassuring data on efficacy and safety. (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation [ARISTOTLE]; NCT00412984).
Authors: U Fan O; Tou Kun Chong; Yulin Wei; Bishow Paudel; Michael C Giudici; Chi Wa Wong; Wai Kit Lei; Jian Chen; Wei Wu; Kan Liu Journal: Int J Cardiol Heart Vasc Date: 2022-03-28
Authors: Sara Reda; Elena Thiele Serra; Jens Müller; Nasim Shahidi Hamedani; Johannes Oldenburg; Bernd Pötzsch; Heiko Rühl Journal: Front Cardiovasc Med Date: 2022-03-31
Authors: David W Louis; Kevin F Kennedy; Marwan Saad; Greg Salber; Hafiz Imran; Tyler Wark; Cullen Soares; Dhairyasheel Ghosalkar; Rasan Cherala; Athena Poppas; J Dawn Abbott; Herbert D Aronow Journal: Am J Cardiol Date: 2022-08-13 Impact factor: 3.133
Authors: Bernadetta Bielecka; Iwona Gorczyca-Głowacka; Beata Wożakowska-Kapłon Journal: Int J Environ Res Public Health Date: 2022-09-21 Impact factor: 4.614
Authors: Anh Vu; Tao T Qu; Rachel Ryu; Shuktika Nandkeolyar; Alan Jacobson; Lisa T Hong Journal: Clin Appl Thromb Hemost Date: 2021 Jan-Dec Impact factor: 2.389